Author

Thomas B. Burgess

Observed name: B. Burgess, Thomas

Institutions: Springer Nature (New Zealand), University of Sheffield

Observed institutions: Springer Nature (New Zealand), University of Sheffield

ORCID: 0000-0001-5757-7909

Observed ORCID: 0000-0001-5757-7909

OpenAlex ID: A5125961306

A Fun-Guide to Innate Immune Responses to Fungal Infections

2022 · Thomas B. Burgess, Alison M. Condliffe, et al. · Journal of Fungi · 46

Candida spp. suppress neutrophil reactive nitrogen species to evade killing

2026 · Thomas B. Burgess, Ffion R. Hammond, et al. · mBio · 2

Individualise chronic non-cancer pain management and opioid deprescribing in older adults

2026 · Thomas B. Burgess, Connie Kang · Drugs & Therapy Perspectives

Recaticimab in primary hypercholesterolaemia and mixed dyslipidaemia: a profile of its use

2026 · Thomas B. Burgess, Hannah A. Blair · Drugs & Therapy Perspectives

Recaticimab in primary hypercholesterolaemia and mixed dyslipidaemia: a profile of its use

2026 · B. Burgess, Thomas, Blair, Hannah A. · Figshare

Add dupilumab and mepolizumab to the toolbox for patients with chronic obstructive pulmonary disease and type 2 inflammation

2026 · Thomas B. Burgess, Connie Kang · Drugs & Therapy Perspectives

Protect older adults from influenza with vaccination and early antivirals

2026 · Thomas B. Burgess, Connie Kang · Drugs & Therapy Perspectives

Consider trofinetide for symptom management in Rett syndrome, with new therapies requiring further study

2026 · Thomas B. Burgess, Sheridan M. Hoy · Drugs & Therapy Perspectives

Consider brexpiprazole for agitation in Alzheimer’s disease, with new therapies under investigation for agitation and psychosis

2026 · Thomas B. Burgess, Simon Fung · Drugs & Therapy Perspectives

Works count: 9

Citation count: 48

H-index: 2

I10-index: 1